Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients

Read full release

Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine

Read full release

Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response

Read full release

First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients

Read full release

Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate

Read full release

Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy

Read full release